Autoimmune hemolytic anemia ≈ Autoimmune hemolytic anemia
View article
Pure red cell aplasia Open
Pure red cell aplasia (PRCA) is a syndrome defined by a normocytic normochromic anemia with severe reticulocytopenia and marked reduction or absence of erythroid precursors from the bone marrow. Diamond-Blackfan anemia is a congenital form…
View article
Sutimlimab in Cold Agglutinin Disease Open
In patients with cold agglutinin disease who received sutimlimab, selective upstream inhibition of activity in the classic complement pathway rapidly halted hemolysis, increased hemoglobin levels, and reduced fatigue. (Funded by Sanofi; CA…
View article
How I treat autoimmune hemolytic anemia Open
Autoimmune hemolytic anemia (AIHA) is an uncommon entity that presents diagnostic, prognostic, and therapeutic dilemmas despite being a well-recognized entity for over 150 years. This is because of significant differences in the rates of h…
View article
Novel insights into the treatment of complement-mediated hemolytic anemias Open
Complement-mediated hemolytic anemias can either be caused by deficiencies in regulatory complement components or by autoimmune pathogenesis that triggers inappropriate complement activation. In paroxysmal nocturnal hemoglobinuria (PNH) he…
View article
Autoimmune hemolytic anemia Open
The diagnosis of autoimmune hemolytic anemia (AIHA) can be made with a stepwise approach that aims to identify laboratory and clinical evidence of hemolysis and then determine the immune nature of hemolysis with the direct anti-globulin te…
View article
Autoimmune complications of COVID‐19 Open
Coronavirus disease 2019 (COVID‐19) is still propagating a year after the start of the pandemic. Besides the complications patients face during the COVID‐19 disease period, there is an accumulating body of evidence concerning the late‐onse…
View article
Pediatric Evans syndrome is associated with a high frequency of potentially damaging variants in immune genes Open
Evans syndrome (ES) is a rare severe autoimmune disorder characterized by the combination of autoimmune hemolytic anemia and immune thrombocytopenia. In most cases, the underlying cause is unknown. We sought to identify genetic defects in …
View article
New Insights in the Pathogenesis and Therapy of Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia Open
Autoimmune hemolytic anemias mediated by cold agglutinins can be divided into cold agglutinin disease (CAD), which is a well-defined clinicopathologic entity and a clonal lymphoproliferative disorder, and secondary cold agglutinin syndrome…
View article
Warm antibody autoimmune hemolytic anemia Open
Autoimmune hemolytic anemia (AIHA) is a rare and heterogeneous disease that affects 1 to 3/100 000 patients per year. AIHA caused by warm autoantibodies (w-AIHA), ie, antibodies that react with their antigens on the red blood cell optimall…
View article
The Changing Landscape of Autoimmune Hemolytic Anemia Open
Autoimmune hemolytic anemia (AIHA) is a greatly heterogeneous disease due to autoantibodies directed against erythrocytes, with or without complement activation. The clinical picture ranges from mild/compensated to life-threatening anemia,…
View article
Autoimmune diseases and myelodysplastic syndromes Open
Immune dysregulation and altered T‐cell hemostasis play important roles in the pathogenesis of myelodysplastic syndromes (MDS). Recent studies suggest an increased risk of MDS among patients with autoimmune diseases. Here, we investigated …
View article
A randomized and double‐blind controlled trial evaluating the safety and efficacy of rituximab for warm auto‐immune hemolytic anemia in adults (the RAIHA study) Open
This Phase 3 multicentre randomized double‐blind and placebo‐controlled trial aimed to compare the efficacy and safety of rituximab (RTX) to placebo for treating newly diagnosed warm autoimmune hemolytic anemia (wAIHA) in adults receiving …
View article
How I treat warm autoimmune hemolytic anemia Open
Warm autoimmune hemolytic anemia (wAIHA) is caused by increased erythrocyte destruction by immunoglobulin G (IgG) autoantibodies, with or without complement activation. Antibody-dependent cell-mediated cytotoxicity by macrophages/activated…
View article
Cold agglutinin disease Open
Primary chronic cold agglutinin disease (CAD) is a well-defined clinicopathologic entity in which a specific, clonal lymphoproliferative B-cell bone marrow disorder results in autoimmune hemolytic anemia. The immune hemolysis is entirely c…
View article
Evans syndrome: clinical perspectives, biological insights and treatment modalities Open
Evans syndrome (ES) is a rare and chronic autoimmune disease characterized by autoimmune hemolytic anemia and immune thrombocytopenic purpura with a positive direct anti-human globulin test. It is classified as primary and secondary, with …
View article
How I treat cold agglutinin disease Open
The last decades have seen great progress in the treatment of cold agglutinin disease (CAD). Comparative trials are lacking, and recommendations must be based mainly on nonrandomized trials and will be influenced by personal experience. He…
View article
Defining autoimmune hemolytic anemia: a systematic review of the terminology used for diagnosis and treatment Open
The terminology applied to autoimmune hemolytic anemia (AIHA) seems inconsistent. We aimed to evaluate the consistency of definitions used for diagnosis and treatment. In this systematic review of literature from January 2006 to December 2…
View article
Evans’ Syndrome: From Diagnosis to Treatment Open
Evans’ syndrome (ES) is defined as the concomitant or sequential association of warm auto-immune haemolytic anaemia (AIHA) with immune thrombocytopenia (ITP), and less frequently autoimmune neutropenia. ES is a rare situation that represen…
View article
Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation Open
New-onset autoimmune hemolytic anemia (AIHA) occurs in 2% to 6% of pediatric patients post–hematopoietic stem cell transplantation (HSCT) and is a significant complication. Incomplete immune recovery following HSCT may predispose to immune…
View article
New Insights in Autoimmune Hemolytic Anemia: From Pathogenesis to Therapy Open
Autoimmune hemolytic anemia (AIHA) is a highly heterogeneous disease due to increased destruction of autologous erythrocytes by autoantibodies with or without complement involvement. Other pathogenic mechanisms include hyper-activation of …
View article
Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial Open
Cold agglutinin disease is a difficult-to-treat autoimmune hemolytic anemia in which immunoglobulin M antibodies bind to erythrocytes and fix complement, resulting in predominantly extravascular hemolysis. This trial tested the hypothesis …
View article
Hematologic complications of immune checkpoint inhibitors Open
Immune checkpoint inhibitors are a class of antineoplastic therapies that unleash immune cells to kill malignant cells. There are currently 7 medications that have been approved by the US Food and Drug Administration for the treatment of 1…
View article
How I manage patients with cold agglutinin disease Open
Summary Cold agglutinin disease ( CAD ) is an uncommon autoimmune haemolytic anaemia in which a well‐defined, clonal low‐grade lymphoproliferative disorder of the bone marrow results in erythrocyte destruction mediated by the classical com…
View article
Autoimmune diseases and HIV infection Open
To describe the clinical manifestations, treatments, prognosis, and prevalence of autoimmune diseases (ADs) in human immunodeficiency virus (HIV)-infected patients.All HIV-infected patients managed in the Infectious Diseases Department of …
View article
Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study Open
Not available
View article
Autoimmune Hemolytic Anemia as a Complication of Nivolumab Therapy Open
Recently, immunotherapeutic drugs, including PD-1 inhibitors (nivolumab, pembrolizumab), PD-L1 inhibitors (atezolizumab, avelumab), and CTLA4 inhibitors (ipiliumumab), have emerged as important additions to the armamentarium against certai…
View article
The diagnostic protocol for hereditary spherocytosis‐2021 update Open
Background Hereditary spherocytosis (HS), a commonly encountered hereditary hemolytic disease, is mostly inherited in an autosomal dominant manner. The clinical manifestations in patients with HS show obvious heterogeneity. Moreover, the s…
View article
Immunotherapy-Associated Hemolytic Anemia with Pure Red-Cell Aplasia Open
The authors report a case of immunotherapy-associated autoimmune hemolytic anemia with pure red-cell aplasia in a patient receiving the anti–PD-1 antibody pembrolizumab for therapy of mucosal malig...
View article
Venous thromboembolic events during warm autoimmune hemolytic anemia Open
Thrombotic manifestations are a hallmark of many auto-immune diseases (AID), specially of warm autoimmune hemolytic anemia (wAIHA), as 15 to 33% of adults with wAIHA experience venous thromboembolic events (VTE). However, beyond the presen…
View article
Efficacy and safety of rituximab for systemic lupus erythematosus‐associated immune cytopenias: A multicenter retrospective cohort study of 71 adults Open
The aim of the study was to assess the efficacy and safety of rituximab (RTX) for treating systemic lupus erythematosus (SLE)‐associated immune cytopenias. This multicenter retrospective cohort study of adults from French referral centers …